About: fang

BAD HOMBURG, GERMANY, Dec 5, 2024 - (ACN Newswire via SeaPRwire.com) - Maxon, maker of powerful, approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects, and more, today released updates across its Maxon One product suite, with new features in Cinema 4D, Redshift, ZBrush and ZBrush for iPad, and Red Giant. The release fulfills artists' holiday wishlists with new capabilities that enhance everyday workflows and improve quality of life for artists, animators, VFX professionals, and studios.Image courtesy of Patrick 4DWhether it's crafting unique models using brand new Cinema 4D Booleans that give cookie-cutter a whole new meaning or bringing a dazzling snowfall to life with Cinema 4D Particles, Maxon One makes it all possible. GoZ in ZBrush for iPad now makes it even easier to transfer creations from the comfort of your couch to the power of your PC or Mac, where the magic of ZBrush, Cinema 4D, Red Giant and Redshift bring those visions to life."From broadcast and film to branding, character creation to world-building, there is no corner of art and design that Maxon One tools do not touch, and with every new release, we aim to make the lives of creative professionals that much easier and more enjoyable - and what better time to bring the joy than the holidays?" said Philip Losch, CPTO of Maxon. "This update delivers improvements based on community input, from the powerful new Boolean workflows in Cinema 4D to cross platform workflows with ZBrush for iPad. Each enhancement inspires innovation across diverse creative fields that permeate through our everyday lives, whether that's on the screen, in the creation of consumer goods or architectural design, and even medical animation of world-changing ideas."Baking Holiday Magic With Patrick 4D3D artist and "Digital Chef" Patrick 4D, who specializes in digital photorealism for food and products, is teaming up with Maxon to bake up some digital goodies for the holiday season: a collection of gingerbread cookies crafted in ZBrush. Available now in the trial or full version of ZBrush, artists can make the cookies their own with tasty decorations and world building. To join in on the fun, share your creations with the Maxon community by tagging @maxonvfx on Instagram.Models That are Anything but Cookie-Cutter with Cinema 4DCinema 4D 2025.1 introduces a completely new Boolean generator that allows artists to easily create complex shapes from animated elements, streamlining the modeling process through intuitive shape addition and subtraction. This new algorithm is faster and more robust, enabling users to work with complex geometry while maintaining high frame rates, even with intricate animated booleans. The flexible user interface allows for the combination of multiple inputs and operations into a single boolean object, a significant upgrade from the previous limitation of just two inputs.In Cinema 4D, precise control over particle behavior is now possible with custom properties and the Particle Node Modifier, part of the growing GPU-accelerated Unified Simulation toolset, offering greater flexibility and creativity. Existing customers will appreciate quality-of-life improvements in Cinema 4D, including enhanced USD import/export and improvements to XRef performance and reliability for seamless collaboration. Interactive tutorials in the Learning Panel combine video guidance and UI highlights to simplify concepts and accelerate the learning process.Redshift Renders Really Fly With an AI Boost and Improved VisualizationRedshift combined with Cinema 4D and ZBrush are the ultimate building blocks for character and product design and architectural visualization, empowering creative professionals to craft breathtaking designs and models that transport clients to new dimensions. Redshift 2025.2 brings continued improvements to Toon rendering, even faster renders in ZBrush and Cinema 4D, and support for fully three-dimensional contours.Tightening of the Substance integrations gives users a fantastic workflow across Adobe and Maxon solutions (available as a bundle). Redshift Random Material Switch makes it easy to vary materials across MoGraph clones and other objects, while improved cross-platform AI-based denoising enables faster and more efficient renders.Creativity Unwrapped with ZBrush (for iPad)The cross-platform compatibility for ZBrush creations continues to see enhancements, with the ability to transfer with just a few clicks from iPad to desktop, where artists can refine, add animation and materials, and render. The complete workflow from concept to render starts the moment creativity strikes thanks to GoZ technology, and for the first time, artists can exchange creations bidirectionally between ZBrush for iPad and Cinema 4D. GoZ has also simplified the process of sending ZBrush sculpts to the 2025 versions of Maya and 3DSMAX.ZBrush desktop also now includes faster Redshift rendering, with denoising and separate AOV passes for shadows, reflections and more to more easily composite in Photoshop. The Anchor Brush in ZBrush for Desktop now has a new Bend mode, allowing users to easily pose characters using two anchor points.Additional updates to ZBrush for iPad, released in November, include UV and texture mapping, surface noise, localization, and improved support for Apple Pencil Pro. ZBrush for iPad includes nearly all the power of the full desktop application, and Maxon continues to close the gap with popular features to customize surfacing.Feeling Festive and On-Trend with Red Giant and Maxon StudioMaxon One's powerhouse for adding personal or branded flair to any project, Red Giant 2025.2 includes updates in Maxon Studio and Universe that make it easy for content creators to level up their videos with on-trend effects, transitions and motion templates. 2D Motion Designers and Compositors can get started easily with the help of Maxon Studio, an After Effects templating toolkit that offers hundreds of customizable graphics and effects, including a set of meticulously crafted Film Title templates. And, always on trend, Universe and Red Giant subscribers can now make use of six new Pixel Dither effects for effortless pixel art creation, using advanced dithering effects that capture the essence of retro gaming and animation.About MaxonMaxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon's innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.Press ContactMegan FasyGrithaus Agency(e) megan@grithaus.agency(p) +1 (617) 480-3674SOURCE: Maxon Computers Copyright 2024 ACN Newswire via SeaPRwire.com.

MUNICH, GERMANY | DRESDEN, GERMANY | TEL AVIV, ISRAEL, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - Autobrains, a leader in automotive artificial intelligence (AI), has joined forces with JOYNEXT, a global automotive Tier-1 supplier and development partner to renowned car manufacturers for over 20 years, to offer their groundbreaking Smart Camera ADAS solution. The camera hardware and optimized control software, provided by JOYNEXT, is powered by Autobrains' Affordable Safety ADAS software. The single-box Smart Camera solution, optimized for cost-effective Advanced Driver Assistance Systems (ADAS), was designed to meet the evolving needs of global Original Equipment Manufacturers (OEMs). This compact system simplifies integration, reduces costs, and ensures regulatory compliance without sacrificing performance.With ever increasing global regulations, smart cameras are a must-have in new build vehicles. The joint Smart Camera meets stringent global safety standards, including Europe's General Safety Regulation (GSR) and Euro NCAP requirements, ensuring its readiness for widespread deployment across vehicle classes. "Building a powerful ecosystem is crucial in order to be able to offer our global customers reliable and future-oriented technologies," says Stavros Mitrakis, CEO of JOYNEXT GmbH. "Autobrains is a fitting partner. With them, we will be able to offer reliable, high-quality, and cost-effective technologies in the field of automated driving in the future."Affordable Safety AI Software"Our new Affordable Safety ADAS solution leverages Autobrains' signature-based self-learning Liquid AI technology, delivering unparalleled efficiency and significantly lowering training, validation, and BOM (Bill of Materials) costs," explains Igal Raichelgauz, Founder and CEO of Autobrains. "By indexing and compressing data into sparse binary representations, the AI system requires less computational power, reducing the size and cost of the SoC (System-on-Chip) and sensor needed for operation." Autobrains' Liquid AI mimics human brain functionality, reducing reliance on labeled data, accelerating development cycles, and minimizing data bias. This hardware-agnostic solution offers OEMs the flexibility to integrate it into existing hardware environments, making ADAS accessible to a wider range of vehicles, from premium models to compact cars, without compromising safety or performance.ADAS as a Standard FeatureDriver assistance systems are becoming standard in all vehicle segments and regions thanks to stronger regulations and NCAP safety ratings. "Providing these assistance systems cost-efficiently to car manufacturers and drivers is a challenge for the industry," says Manuel Yoon, General Manager Germany and VP Strategy of Autobrains. "Our contribution is to help reduce the number of accidents by providing technology that enables autonomous emergency braking, lane-keeping support, and intelligent speed assistants for everyone. In addition, we can reduce the drivers' burden with comfort features such as adaptive cruise control with a single camera."Streamlined ScalabilityThe system eliminates the need for complex multi-component systems, reducing time-to-market while enhancing scalability. "Our smart camera combines data collection, processing and control in one compact device. There are expansion stages with an additional interior camera, which means the system can also meet driver monitoring requirements within a single module. This makes our products an attractive solution, especially for European and Asian OEMs." emphasizes Jan Kolanko, Senior Manager for ADAS at JOYNEXT GmbH.The new Smart Camera ADAS solution will be available for OEMs worldwide starting in early 2025. This groundbreaking solution aims to democratize advanced safety technologies, making them accessible to a broader range of vehicles and markets.For more information about Autobrains and its innovative AI solutions, please visit www.autobrains.ai.Autobrains - We Drive AIAutobrains is a leading AI company in the automotive industry. Autobrains invented and developed a paradigm-shifting AI technology: Liquid AI - backed by 250+ patents addressing autonomous driving challenges. Implementing this unique AI technology for ADAS applications disrupts the market with its unprecedented perception capabilities, low compute requirements, and agnosicity to sensors and SoCs. The company is backed by strategic investors including Temasek, Knorr-Bremse, BMW i Ventures, Toyota Ventures, VinFast, Continental, and Autel.JOYNEXT - WE CONNECT FUTUREIntelligent solutions for connected vehicles - that's JOYNEXT. We are working on future technologies that are becoming increasingly important for car manufacturers and their customers. On the road to autonomous driving, data communication between the vehicle and mobile devices such as smartphones, with other vehicles (V2V) or with infrastructure systems (V2I) is becoming increasingly important. JOYNEXT is also involved in the new and further development of cloud-based services.JOYNEXT always strives for a balance between innovation and sustainability. When developing our products, we focus on the end user and their needs and usage behavior.With more than 1,500 employees worldwide, JOYNEXT takes connected car technologies to a new level. We are present at seven locations; our development and innovation centers are located in Dresden (Germany) and Ningbo (China).JOYNEXT is a direct supplier to the automotive industry and has been a development partner and system supplier to renowned car manufacturers for over 20 years. Our technologies in the areas of connected infotainment and smart connectivity gateways can be found in millions of vehicles worldwide. www.JOYNEXT.comContact InformationSophia EichlerDirector of Marketingmedia@autobrains.ai+49 15167066494Source: Autobrains Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) – CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is pleased to announce the winning of three industry awards, affirming CITIC Telecom CPC’s unwavering   commitment to cybersecurity excellence, recognizing the deep industry expertise of its professional team, strong cybersecurity awareness among its workforce and cutting-edge innovative solutions to meet the growing cybersecurity demand and combat the increasingly rampant cyber threats and challenges.The three industry awards are:- Hong Kong Internet Registration Corporation Limited (HKIRC) - Platinum Award in Cyber Security Staff Awareness Recognition Scheme 2024;- Top Managed Security Service Provider (MSSP) of the Year 2024, by Fortinet;- Top Partner Enterprise Business FY24, by Green RadarMr. Brook Wong, Chief Executive Officer of CITIC Telecom CPC, said, “The three industry accolades are a testament to our commitment to foster internal ‘Human Firewall’ culture in our company while providing cutting-edge security solutions externally through our cybersecurity experts, showcasing our solid foundation in both internal and external cybersecurity excellence. These industry recognitions inspire us to further elevate cybersecurity awareness and innovative solutions, unleashing more market opportunities and jointly nurturing high-quality industry development. We lead the market with our dedicated approach to promoting advanced security solutions "TrustCSI™ 3.0", solidifying our position as a cybersecurity leader in digital defense.”  HKIRC Cyber Security Staff Awareness Recognition SchemeCo-organized by The Hong Kong Internet Registration Corporation Limited (HKIRC) and ISACA China Hong Kong Chapter (ISACA), Cyber Security Staff Awareness Recognition Scheme was completed. Participating organizations include SMEs and large enterprises in banking, property management, retail and other industries. The Scheme aims to recognize organizations that are aware of the importance and have implemented suitable measures to enhance cybersecurity staff awareness within their organizations in the past 12 months. The Scheme enhances organizations’ protection level by encouraging the organizations to promote “Human Firewall” concept through multiple channels such as training, policy, communication, drill, etc. The top-tier Platinum Award requires the fulfilment of all the five assessment criteria including cybersecurity training, phishing drill participation, comprehensive cybersecurity policy, reporting channels for cybersecurity issues and dissemination of cybersecurity information.CITIC Telecom CPC has clinched the prestigious Platinum Award in recognition of its dedication to enhancing network security technologies, comprehensive optimiziation of systems and policies, and the introduction of "TrustCSI™ 3.0" cybersecurity solution, innovative service framework and proactive defense technologies to respond to ever-increasing network threats. CITIC Telecom CPC also cultivates a culture of cybersecurity awareness among its staff through global staff training and cybersecurity drills, building a second level of defense line for the company to defend and effectively address ever-changing security threats. Collaborate to Succeed: Building a Robust Defense EcosystemsCITIC Telecom CPC achieved various prestigious awards from two cybersecurity ecosystem    partners Fortinet and Green Radar, demonstrating its excellent collaboration capabilities in global cooperation strategies and cybersecurity. CITIC Telecom CPC has not only met the market demand for cybersecurity solutions, but also surpassed competitors through continuous technological innovations and close collaborations with ecosystem partners, including the launch of "TrustCSI™ 3.0" cybersecurity solutions in 2023, which enhances the core service capabilities of the   Security Operations Center (SOC) to provide enterprises with proactive defense, integrate AI applications into their business, and optimize their intelligent operations.CITIC Telecom CPC has been bestowed "Top Managed Security Service Provider of the Year 2024" by Fortinet, a testament to the company's excellence in providing cutting-edge managed security services that exceed industry standards. In addition, CITIC Telecom CPC has been recognized as the "Top Partner Enterprise Business FY24" by Green Radar, which underscores CITIC Telecom CPC's strategic collaborations with partners to provide innovative solutions to address unique cybersecurity needs of enterprise clients.Proactively Elevating Network Security and Innovative Technologies Internally and ExternallyCITIC Telecom CPC actively pursues excellent cybersecurity capabilities, both internally and externally. Internally, CPC fosters a culture of cybersecurity awareness. Its staff have demonstrated cybersecurity best practices by always staying vigilant and employing proactive defense in the workplace, thus safeguarding the company’s digital assets. Externally, CITIC Telecom CPC is committed to be a trusted TechOps Security Enabler for enterprises. With a passion for innovation and excellence, its cybersecurity experts team provides professional services and tailored innovative solutions, empowering enterprises to navigate the digital landscape with confidence and resilience.With the motto “Innovation Never Stops”, CITIC Telecom CPC continues to integrate AI technology into its information security products portfolio to provide advanced cybersecurity solutions for addressing the evolving network threats. The newly-launched TrustCSI™ AI Pentest service functions as an AI robot cleaner which automatically operates 24x7, helping enterprises identify key vulnerabilities in the network and establish a robust defense against potential threats. CITIC Telecom CPC introduces a special offer which includes TrustCSI™ AI Pentest and Attack Surface Management (ASM) for internal and external vulnerabilities scanning, enhancing customers’ resistance to vulnerabilities and systematically improving identification, prioritization and remediation of vulnerabilities, and continuous monitoring of hacking attempts. Enterprise security management strategy can be elevated through multiple defense measures to mitigate potential network attack risks. For special offer details, please visit https://www1.citictel-cpc.com/promotion/2411XmasOffer/index-EN.html.About CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI).  Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across nearly 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SDWAN gateways, 21 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises.  We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.  For more information, please visit www.citictel-cpc.com.Media Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536Email: catherine.yuen@citictel-cpc.com Copyright 2024 ACN Newswire via SeaPRwire.com.

Delaware, USA, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - As the digital world is increasingly threatened by advanced cyberattacks and looming quantum computing challenges, Naoris Protocol unveils groundbreaking technology that revolutionizes digital security through the world's first Post-Quantum powered Decentralized Physical Infrastructure Network (DePIN) for cybersecurity and digital trust.Backed by prominent figures including DNS designer David Holtzman, former White House Chief of Staff Mick Mulvaney, and Shanfari & Partners Chairman H.E. Sheikh Thamer Said Ahmed al-Shanfari, this innovative protocol transforms traditional untrusted devices into a decentralized security layer of cyber-trusted validator nodes, eliminating single points of failure that plague centralized security systems.Decentralized Security: A Necessary Shift Amidst Rising Centralized FailuresThe launch comes at a critical time, following the CrowdStrike outages in July 2024 that demonstrated the vulnerabilities of centralized security frameworks. These incidents disrupted global services across aviation, banking, and media sectors, highlighting the urgent need for decentralized security solutions."Current centralized models are vulnerable by design," states David Carvalho, CEO & Founder of Naoris Protocol."Our protocol decentralizes digital security, where every device becomes a secure validator node as part of a trusted, incentivized layer that uses post-quantum cryptography to create a real time, decentralized validation brain."The protocol introduces four key innovations:Post-Quantum Security: Designed to withstand quantum computing, ensuring sensitive data and blockchain infrastructures are protected from next-generation cyber threats.Decentralized Security Layer: Devices actively validate and prove their trusted state in real time, creating a self-reinforcing security layer that scales without weakening.Incentivized Security Model: Devices are rewarded for maintaining security validations across the network to continually reinforce cyber defenses.Real-Time Validation: Continuous verification of node integrity mitigates risks of compromise or collusion, a stark contrast to static and reactive centralized systems.Impact on Expanding DePIN EcosystemsWith the DePIN market projected to reach $3.5 trillion by 2028, Naoris Protocol positions itself as the critical security DePIN for both Web2 and Web3 infrastructures. As DePIN expands into various industrial applications, the protocol provides essential infrastructure for DePIN ecosystems across cloud computing, storage, wireless and energy, offering unprecedented cyber resilience for community compute network models.DNS pioneer David Holtzman, serving as Chief Strategy Officer, emphasizes: "Naoris Protocol is not just another blockchain project; it's the security backbone that enables the entire DePIN sector to thrive safely. This could be the catalyst that propels decentralized infrastructures into mainstream adoption."Incentivized Testnet LaunchThe upcoming Testnet launch will allow users to participate in stress-testing this revolutionary system. Validating and maintaining security standards, while counteracting threats like phishing and network breaches, the testnet will lay the groundwork to seed a global post-quantum cybersecurity DePIN.For Testnet participation, visit https://naorisprotocol.network/For more information, visit https://www.naorisprotocol.com/  Naoris Protocol is available for interviews and technical demonstrations of their groundbreaking DePIN solution for cybersecurity and digital trust.Check out our White PapersStay connected: Twitter | Discord | Telegram | LinkedInContact: Guy DaviesCMO, Naoris ProtocolGuy@Naoris.com   Copyright 2024 ACN Newswire via SeaPRwire.com.

- Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission.- In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved immunological complete remission by week 24.- EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported.SHANGHAI, Dec 4,  2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK,“Everest”, or the "Company"),  a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. In an analysis of the data available as of September 13th, 2024, results from the Phase 1b/2a clinical trial showed that for patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission1 and 10 out of 11 (91%) achieved immunological complete remission (ICR)2. In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved ICR by week 24.EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of autoimmune renal diseases. Compared to covalent irreversible BTK inhibitors, EVER001 offers improved selectivity while maintaining high potency, thereby potentially avoiding many of the side effects associated with earlier-generation BTK inhibitors. Everest Medicines holds global rights to EVER001 for the treatment of renal diseases.The Phase 1b/2a clinical trial of EVER001 for the treatment of pMN is an ongoing trial conducted in China. A total of 31 patients with biopsy-proven pMN who tested positive for anti-PLA2R autoantibodies were enrolled into two cohorts. The total treatment duration was 36 weeks. Based on the patient data collected by September 13th, 2024, in the low-dose cohort, the geometric least squares mean 24-hour proteinuria decreased by 78.3% at week 36 compared to baseline, while the high-dose cohort achieved a 73.8% reduction by week 24. EVER001 treatment induced greater than 90% reductions in anti-PLA2R antibody as early as week 24 in the low-dose cohort and week 12 in the high-dose cohort. EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported."We are excited to see the encouraging results in this preliminary analysis of our Phase 1b/2a clinical proof-of-concept trial of EVER001. This demonstrates the potential of EVER001 as a next-generation BTK inhibitor for the treatment of various autoimmune renal diseases, including pMN. "Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said："This data release marks the first time Everest Medicines has disclosed results from its global pipeline. We look forward to completing this trial and sharing detailed data in future conferences and publications. Moving forward, we will continue to drive the global clinical development of EVER001, to meet patients' urgent clinical needs.”Membranous nephropathy is a common pathological type of nephrotic syndrome in adults, and its prevalence in China has been increasing, ranking second only to IgA nephropathy3. There are about 2 million patients with pMN in China, with an estimated 80,000 to 100,000 patients in the United States, 80,000 in Europe, and 40,000 in Japan. There are no approved drugs for this indication worldwide. The current treatment goal is to improve remission rates, reduce high relapse rates, and minimize the risk of chronic toxicity caused by currently available treatments. More than one-third of pMN patients still progress to end-stage renal disease under current standards of care.This Phase 1b/2a clinical trial was approved by the Center for Drug Evaluation of the National Medical Products Administration in September 2022 to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of EVER001 in Chinese patients with glomerular diseases characterized by proteinuria. The previously published results of a Phase 1 study conducted in healthy Chinese and Australian subjects conducted by SinoMab BioScience indicate that EVER001 has high selectivity, excellent pharmacokinetic properties, a good safety profile, and strong target binding.About EVER001EVER001 (previously known as XNW1011) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases. Based in part on results from a completed phase 1 trial with healthy subjects conducted by SinoMab in China, EVER001 exhibited high selectivity, excellent pharmacokinetics properties, strong target binding and a safety profile that supports continued clinical development.Under an exclusive licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience, Everest owns global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases.Investor Calls InformationEverest Medicines will hold investor calls on the data results from EVER001 Phase 1b/2a clinical study in primary membranous nephropathy. EVER001 is a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, and Everest owns the global rights to develop EVER001 for the treatment of renal diseases.The English session of the conference call will be held at 9:00 AM on Dec. 4, 2024, Beijing Time (8:00 PM U.S. Eastern Time on Dec. 3, 2024) and the Mandarin session of the conference call will be held at 10:30 AM Beijing Time on the same day (9:30 PM U.S. Eastern Time on Dec. 3, 2024).The conference calls can be accessed by the following links:For English Session:Time: 9:00 AM Beijing Time, Wednesday, Dec. 4, 2024 (8:00 PM U.S. Eastern Time on Dec. 3, 2024)Pre-Registration Link: https://www.acecamptech.com/eventDetail/60510700Webcast Link:https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700Alternatively, participants may dial in to the conference call using below dial-in information:United States: +1-646-2543594 (EN)Chinese Mainland: +86-10-58084166 (EN), +86-10-58084199 (CN)Hong Kong, China: +852-30051313 (EN), +852-30051355 (CN)United Kingdom: +44-12-1368-0466 (EN)International: +1-866-6363243 (EN)Password: 842080For Mandarin Session:Time: 10:30 AM Beijing Time, Wednesday, Dec. 4, 2024 (9:30 PM U.S. Eastern Time on Dec. 3, 2024)Webcast Link: https://s.comein.cn/n3arj55sAlternatively, participants may dial into the conference call using below dial-in information:United States: +1-646-3578788, +1-408-7093255Chinese Mainland: 400-969-8928, 400-806-3263Hong Kong, China: +852-301-83602Taiwan, China: +886-226563394, +886-277417882Singapore: +65-64075649, +65-66220840United Kingdom: +44-2070970018 International: +86-2362737123Password: 377570The replay of English session will be available shortly after the call and can be accessed by visiting the Company’s website at http://www.everestmedicines.com.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.References:1.Overall clinical remission (complete remission or partial remission): 24h proteinuria complete remission (CR): 24h proteinuria < 0.3g/24 h; 24h proteinuria partial remission (PR): 24h proteinuria < 3.5g/24h, but ≥0.3g/24 h, and reduction > 50%, regardless of eGFR or the serum albumin level from baseline.2. Immunological complete remission (ICR): anti-PLA2R titer < 20RU/ml (negative).3. Expert consensus on the application of rituximab in the treatment of membranous nephropathy, Chin J Intern Med, March 2022, Vol. 61, No. 3. Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - OKX, the leading cryptocurrency exchange, has partnered with DeAgentAI, the first AI-driven feedback incentive protocol in Web3, to launch an exclusive airdrop campaign. Starting December 3rd, users can complete simple tasks on OKX Wallet to win a share of $50,000 worth of DA tokens.Click here to join the campaign: https://www.okx.com/web3/giveawayParticipating in the DeAgentAI and OKX Wallet airdrop is easy. Download the OKX Wallet, follow DeAgentAI social media networks, and complete a few simple tasks such as sharing campaign posts, and you can claim your rewards. The campaign runs from December 3rd for two weeks-don't miss out!This collaboration brings users unparalleled opportunities to explore advanced AI technology while enjoying the benefits of a secure and user-friendly wallet. With rewards of $50,000 worth of DA tokens, the initiative encourages users to explore Web3 in an innovative and incentivized environment. DeAgentAI and OKX Wallet aim to foster adoption and empower users in the rapidly evolving crypto space.About DeAgentAIDeAgentAI is a trailblazer in Web3 technology, introducing the first AI feedback mechanism incentive protocol that achieves "proof of insight" by integrating user feedback into the model training process. Its flagship product, AlphaX, combines advanced MOE and Transformer architectures to predict BTC and ETH price trends with over 80% accuracy.What is OKX's Web3 Wallet?OKX Wallet complements this innovation with its secure and user-friendly interface tailored for decentralized finance (DeFi) and Web3 applications. As a leading wallet in the crypto space, OKX Wallet enables seamless integration with platforms like DeAgentAI, empowering users to engage in token giveaways, explore cutting-edge AI tools, and participate in the rapidly growing Web3 ecosystem.Contact InformationYves-Alexandre d'OuradouFounderdeagent.ai@gmail.com(001) 2024989991Source: DeAgentAI Copyright 2024 ACN Newswire via SeaPRwire.com.

SAN DIEGO, CA, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - The Japan Maritime Self-Defense Force (JMSDF) has selected the General Atomics Aeronautical Systems, Inc. (GA-ASI) SeaGuardian® Remotely Piloted Aircraft (RPA) systems for its Long Endurance Unmanned Aerial Vehicle program. This follows JMSDF use of SeaGuardian since May 2023 as part of its Medium-Altitude, Long Endurance (MALE) RPA System Trial Operations Project.SeaGuardian has been used by JMSDF to conduct various tests including whether unmanned aircraft can supplant some of the missions currently accomplished with manned aircraft. SeaGuardian is a MALE RPA system that can fly for 24 hours or more, depending on the configuration.GA-ASI has strengthened its Maritime Wide Area Surveillance (MWAS) for Japan with Optix+, which gathers information from the SeaGuardian sensors, as well as other data sources, displaying the full picture of surveillance information for its operator. This functionality makes it easy to task and direct its Intelligence, Surveillance and Reconnaissance (ISR) information in real time. GA-ASI's Optix+ software suite rapidly correlates and exploits collected data into an easily shared common operational picture. Having multi-source correlated data enables automatic detection of anomalous behaviors over waters.SeaGuardian features two multi-mode maritime surface-search radars with an Inverse Synthetic Aperture Radar (ISAR) imaging mode, an Automatic Identification System (AIS) receiver, and a High-Definition - Full-Motion Video sensor equipped with optical and infrared cameras as well as electronic intelligence receivers. This sensor suite enables real-time detection and identification of surface vessels over thousands of square nautical miles and provides automatic tracking of maritime targets and correlation of AIS transmitters with radar and electronic intelligence tracks.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.For more information, visit www.ga-asi.com .Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - December 3, 2024) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") a leading North American exploration company focused on critical minerals, acknowledges today's announcement by China banning exports of gallium, germanium, and antimony to the United States. This move underscores the urgent need for Western nations to secure reliable long-term sources of these essential materials.Antimony, a critical component in military applications, energy storage, and advanced manufacturing, is now at the forefront of the global supply chain crisis. China's ban, coupled with existing restrictions that came into effect September 15, 2024, has already sent antimony prices soaring by over 228% this year(1). The Western world faces mounting pressure to address its reliance on China for strategic resources critical to national defense and technological innovation. This ban comes at a time when defense sector inventories are at already concerningly low levels.(2)Military Metals recent antimony mineral project acquisitions in Slovakia, Nova Scotia, and Nevada provide shareholders with a pure antimony play with a diverse portfolio in top jurisdictions."This announcement from China reinforces the importance of Military Metals' mission to secure a sustainable, independent future supply chain for critical minerals," said Scott Eldridge, CEO of Military Metals Corp. "The West can no longer afford to rely on adversarial nations for resources essential to our security and economic stability. We are taking proactive steps to meet this growing demand with future domestic and allied sources of antimony."As geopolitical tensions escalate and the trade war intensifies, Military Metals will continue to prioritize the development of critical mineral resources and work closely with governments and industry partners to ensure the West remains resilient and self-sufficient.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release include exploration activities, and assumptions related to the continuation of the global demand for antimony. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the properties that are the subjects of this news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact both and any future activities in respect of the properties.. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.(1)Reuters; China bans export of critical minerals to US as trade tensions escalate; By Amy Lv and Tony Munroe; December 3, 2024(2)Heritage Foundation: commentary/It’s Past Time to Re-Supply Our Munitions-Depleted U.S. Navy by Jim Fein; June 17, 2024To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232325 Copyright 2024 ACN Newswire via SeaPRwire.com.

TSUKUBA, Japan, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Polymers, such as plastics, are essential in many aspects of life and industry, from packaging and cars to medical devices and optic fibres. Their value comes from diverse properties that are largely determined by their monomers – the single chemical units – that make up a polymer. Unfortunately, it can be challenging to control the chemical behaviour of monomers during manufacture to achieve a desired outcome.The flow synthesis reactor with two bottles containing a monomer, initiator and solvent mixed using a micromixer. The synthesis is controlled with AI-based design of experimental conditions such as the temperature and a flow rate. Now, a team of researchers led by Professor Mikiya Fujii of the Nara Institute of Science and Technology in Japan have used machine learning to mathematically model the polymerization process and reduce the need for time-consuming and expensive experimentation. Their results have been published in the journal Science and Technology of Advanced Materials: Methods.Machine learning algorithms need data, so the researchers designed a polymerization process that would quickly and efficiently generate experimental data to feed into the mathematical model. The target molecule was a styrene-methyl methacrylate co-polymer, which was made by mixing styrene and methyl methacrylate monomers, both already dissolved in a solvent with an added initiator substance, then heating them in a water bath.The team also used a method called flow synthesis, in which the two monomer solutions are mixed and heated in a constant flow. This allows for better mixing, more efficient heating, and more precise control of heating time and flow rate, which makes it ideal for use with machine learning.The modelling evaluated the effect of five key variables in the polymerization process: the concentration of the initiator, the ratio of solvent to monomer, the proportion of styrene, the temperature of the reaction, and the time spent in the water bath. The goal was to have an end product with as close to 50% styrene as possible.Once enough experimental data was available, the machine learning process took only five cycles of calculation to achieve the ideal proportion of styrene to methyl methacrylate. The results showed that the key was a lower temperature and longer time in the water bath, as well as lowering the relative concentration of the monomer in the solvent. The researchers were surprised to discover that the solvent concentration was just as important as the proportion of monomers going into the mix.“Our results demonstrate that machine learning not only can explicitly reveal what humans may have implicitly taken for granted but can also provide new insights that weren’t recognized before,” Professor Mikiya Fujii says. “The use of machine learning in chemistry could open the door for smarter, greener manufacturing processes with reduced waste and energy consumption.”Further informationMikiya FujiiNara Institute of Science and TechnologyEmail: fujii.mikiya@ms.naist.jp Paper: https://doi.org/10.1080/27660400.2024.2425178About Science and Technology of Advanced Materials: Methods (STAM-M)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-M Dr Yasufumi NakamichiSTAM Publishing DirectorEmail: NAKAMICHI.Yasufumi@nims.go.jp Press release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2024 ACN Newswire via SeaPRwire.com.

LONDON, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Spritzer has once again demonstrated its dominance in the bottled water industry by being named "Brand of the Year" in the national beverage division’s Water Category at the prestigious 2024–2025 World Branding Awards. The recognition marks Spritzer’s 10th consecutive win at the global awards, a testament to the brand’s enduring excellence in quality, branding, and consumer trust which further solidifies its position as Malaysia’s leading mineral water brand.Spritzer’s Head of Public Relations, Winnie Chin, accepting the Brand of the Year award under the national beverage division’s Water Category during the recent World Branding Awards at the Tower of London The accolade was awarded by the World Branding Forum (WBF), a global non-profit organization devoted to advancing branding standards worldwide, at the annual World Branding Awards event which recognizes exceptional global and national brands across various categories. Winners in each category were evaluated through a rigorous process involving brand valuation, market research, and online public voting, showcasing a holistic assessment of brand strength and consumer trust. Most importantly, as the award evaluation relies heavily on consumer voting (70%), Spritzer’s continued wins over the years demonstrates the brand’s ability to consistently resonate with audiences and exceed customer expectations.Accepting the award on behalf of Spritzer during the awards ceremony held at the iconic Tower of London was Winnie Chin, Spritzer’s Head of Public Relations, who acknowledged the profound significance of this milestone: “We are honoured to receive this award for the 10th year running. Our achievements would not be possible without the unwavering support of our consumers, whose steadfast loyalty has made the Spritzer brand a household name. We also extend our gratitude to our partners for their collaboration and support and especially to our dedicated team for their hard work and creativity that have made this journey possible. We are deeply humbled and motivated to continue elevating our brand to greater heights, to build on Spritzer’s brand strength and commitment to excellence in all aspects of our company.”The award is a milestone that recognises Spritzer as a benchmark for consistency and adaptability to maintain brand trust and address emerging consumer needs in the ever-evolving market landscape. The company’s consistency, adaptability, and innovation have not only propelled it to the forefront of Malaysia’s bottled water industry but have also established it as a benchmark for quality, sustainability and innovation on a global stage. Spritzer’s decade-long winning streak at the awards exemplifies the brand’s commitment to producing high-quality natural bottled water and its reputation as a consumer-preferred brand.Building on this monumental achievement, Spritzer reaffirms its commitment to quality assurance as it continues to deliver bottled water with natural benefits and premium standards. The brand emphasises its dedication to sustainability goals and innovation as it continues to focus on advancing efforts to become a circular brand by 2030, aligned with global environmental initiatives, while leveraging cutting-edge technologies to introduce consumer-focused solutions to meet emerging needs.For more details about Spritzer, please visit our website at https://www.spritzer.com.my/.About Spritzer:Established in 1989, Spritzer Group has been a pioneer in providing Malaysians with natural mineral water sourced from a 440-acre green rainforest. Committed to innovation, Spritzer Group leads the Malaysian bottled water industry through manufacturing, distribution, marketing, and sales of its diverse product line. From renowned natural mineral water to refreshing non-carbonated fruit-flavoured drinks, each product is carefully crafted to meet consumer needs.Comprising eight business subsidiaries, Spritzer Group specializes in the production and distribution of silica-rich natural mineral water, sparkling natural mineral water, distilled drinking water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.With over 30 years of experience, Spritzer Group is Malaysia's largest and only listed bottled water producer. For more information, please visit www.spritzer.com.my. Copyright 2024 ACN Newswire via SeaPRwire.com.

SAN FRANCISCO, CA & MUMBAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - CleverTap, the all-in-one engagement platform, has released its market research report on “The State of App and Web User Experience Optimization”. The report sheds light on how digital-first brands are leveraging experimentation and personalization on their apps and websites to drive customer engagement and business growth. It also highlights roadblocks faced by marketers and product managers while experimenting with the UI, workflows, and functionality across apps and websites.For a thorough understanding of the current landscape, this report draws insights from a diverse group of respondents – with data gathered through structured surveys and in-depth interviews – representing organizations with over two million customers across 50+ countries. This includes VPs, CMOs, and product managers ranging from startups to large enterprises across various industries. – Together, they offer valuable insights into how businesses optimize app and web experiences to drive customer engagement and business growth.While 95% of surveyed product managers and 88% of marketers believe that the right user experience is essential for driving customer engagement and retention — many report significant challenges to effectively experimenting with app and web user experiences. Despite recognizing its importance, they reported difficulties such as limited resources, data gaps, and technical constraints that hinder their ability to innovate and deliver impactful user experiences. Other notable findings from the report include -81.9% of product managers rarely experiment with their app and web experiences before making changes to them. The top challenges quoted include lack of resources (46%), inadequate data and analytics (31%), and technical issues (19%)54% of product managers are unable to support marketers in experimenting with onboarding flows, banner placement, homepage content and other similar app and web experiences.81% of marketers believe it would make a significant impact if they could independently experiment with multiple variations of web and app experiences within a no-code framework provided by their product management function.Commenting on the report, Jacob Joseph, Vice President - Data Science, CleverTap said, “With consumer expectations constantly rising, brands need to go beyond perfecting their channel strategies and also focus on enhancing the in-app and web experiences to drive results from their marketing efforts. Since all channels ultimately lead users to the app or website, an unsatisfactory experience there can render all your efforts ineffective and become a missed opportunity. Personalization and experimentation on apps and websites are critical to reducing churn and driving growth, yet resource constraints and data gaps hinder marketers and product managers. We are committed to helping businesses navigate these challenges with CleverTap’s Product Experiences, which offers effortless ways to personalize and experiment with app and web experiences driving stronger engagement and lasting brand loyalty."For more information and insights download the report here. About CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Decathlon, Domino’s, Levis, Jio, Emirates NBD, Puma, Croma (A Tata Enterprise), Swiggy, SonyLIV, Axis Bank, AirAsia, TD Bank, Ooredoo, and Tesco to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit clevertap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/  X: https://twitter.com/CleverTap  Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications, CleverTap+91 9820900036sony@clevertap.comASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.

SAN DIEGO, CA, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - On November 19, 2024, General Atomics Aeronautical Systems, Inc. (GA-ASI) hosted its first Blue Magic Netherlands (BMN) event in Eindhoven, the Netherlands. Approximately 200 people attended the event that provided Dutch businesses with an opportunity to present their capabilities to GA-ASI and other companies interested in possible collaborations. GA-ASI was joined for the event by the Netherlands Ministry of Economic Affairs, the Netherlands Ministry of Defence, Lockheed Martin Ventures, Brainport Development, Brabant Development Agency (BOM), the Netherlands Industries for Defence & Security (NIDV), and SpaceNED.At this event, GA-ASI and its partners heard first-hand from Dutch companies about the important capabilities they are developing. The process started in July when GA-ASI put out an open invitation to Dutch businesses to apply for the opportunity to present innovative technologies at the November 19 event. Key areas of focus included Artificial Intelligence/Machine Learning, Autonomy, Advanced Materials, Sensors, Advanced Manufacturing, and Space. Close to 50 companies applied and after reviewing the applications, 15 businesses were selected to pitch their capabilities to an audience that included lightweight lattice structures, gas detection technologies, advanced battery and photonics applications, and several innovative unmanned system and AI applications, among many others."This event is where the rubber meets the road," said Brad Lunn, Managing Director-Strategic Finance at GA-ASI. "In addition to attracting many companies, we increased the areas of expertise and depth of knowledge from the presenting companies in order to provide research, development, and breakthrough innovations to support current and future missions by GA-ASI aircraft. We also wanted to give the companies an opportunity to pitch in front of other potential customers, partners, and investors."The first Blue Magic event held by GA-ASI was in 2019 in Belgium, with subsequent events held in 2020, 2021, and 2023. GA-ASI is delivering eight MQ-9A Remotely Piloted Aircraft to the Royal Netherlands Air Force (RNLAF).GA-ASI expects to announce technology partnerships stemming from the BMN event and intends to hold this event on an annual basis in the Netherlands.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable remotely piloted aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - December 2, 2024, In the context of the Belt and Road Initiative, the first Belt and Road Golden Route Series Financial Promotion Event——the Kyrgyz Republic Ministry of Finance's promotional seminar and non-deal roadshow was successfully held today in Hong Kong. The event was jointly hosted by TF International Securities Group Limited ("TF International") and China CITIC Bank International Limited ("China CITIC Bank International"), attracting numerous international investors and financial industry leaders.The Kyrgyz Republic, as one of the earliest countries to support and engage in the Belt and Road Initiative, has seen increasingly close economic and trade relations with China. Recently, TF International signed a memorandum of understanding with the Kyrgyz Republic Ministry of Finance, becoming the first Hong Kong-based Chinese securities firm to establish an official partnership with the Kyrgyz Republic Ministry of Finance. The two parties work together to promote the RMB internationalization, support the real economy, facilitate high-quality development, and reinforce Hong Kong’s position as an international financial center. The event featured distinguished guests, including Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of Kyrgyz Republic, Mr. Abdybapov Abdanbek Abdybapovich, Head of the Government Borrowing Department of Kyrgyz Republic, Mr. CHAN Ho Lim, Joseph, JP, Under Secretary for Financial Services and the Treasury of Hong Kong S.A.R., and Mr. ZOU Chuan, CEO of TF International, as well as Mr. Andy Siow, Senior Coverage Banker, DCM, at China CITIC Bank International. They shared insights into Kyrgyzstan’s development opportunities and investment prospects in the international financial market, discussing investment opportunities and key focus areas for mutually beneficial cooperation. In his opening speech, Mr. CHAN Ho Lim, Under Secretary for Financial Services and the Treasury of Hong Kong, remarked, "Hong Kong has firmly established itself as Asia’s leading international financial centre. Our core strengths include free flow of capital and information, a robust common law system, and a simple and low tax regime, and Hong Kong enjoys preferential access to Mainland China. All these position Hong Kong as the super-connector between China and international markets, which plays a key role in promoting RMB internationalization and advancing the Belt and Road Initiative. The Kyrgyz Republic is an important partner under the Belt and Road Initiative and is certainly Hong Kong’s important trading partner in Central Asia.” He also stated that, “I would like to express my gratitude to the Kyrgyz Republic Ministry of Finance and TF International and appreciate your commitment to fostering stronger ties between Central Asia and Hong Kong. We look forward to exploring potential future collaborations with the Kyrgyz Republic that will benefit our respective markets and promote partnerships among Belt and Road nations.” As of September 1, 2024, Renminbi (RMB) has been included in the list of official daily exchange rates published by Kyrgyzstan, alongside the US dollar, euro, Russian ruble, and Kazakh tenge. This move further strengthens economic and financial cooperation between the two countries. Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of the Kyrgyz Republic, stated, "The inclusion of the RMB in the list of official daily exchange rates in Kyrgyzstan marks a new stage in the economic cooperation between the two countries. This not only provides greater convenience for international investors but also empowers the development of Kyrgyzstan's financial market. Through this promotional event, we hope to connect with more international investment institutions and jointly promote the sustainable development of the regional economy." Hong Kong, as the international financial center and the central city of the Guangdong-Hong Kong-Macao Greater Bay Area, plays an important bridging role in the Belt and Road Initiative, leveraging its diverse financing channels and close alignment with national strategies. Mr. ZOU Chuan, CEO of TF International, stated, "The Belt and Road Initiative offers significant opportunities for economic integration and development, enhancing trade across Asia, Europe, the Middle East, and beyond. As a gateway between China and the world, Hong Kong is a key hub for the internationalization of the Renminbi, facilitating its use in trade and investment, and supporting effective currency risk management for BRI projects. With ongoing economic expansion and the internationalization of the Renminbi, Hong Kong is well-positioned to emerge as the premier financing hub. As we explore upcoming opportunities, I encourage you to envision the transformative impact these initiatives can have on the Kyrgyz Republic’s development agenda and the broader economic landscape of Central Asia. Together, we can unlock new avenues for growth and collaboration." From December 3 to 6, 2024, TF International, in collaboration with China CITIC Bank International will join forces with the Kyrgyz Republic Ministry of Finance in hosting a series of non-deal roadshows in Shanghai and Beijing, further strengthening ties with the Chinese financial market. The success of today’s promotional seminar and non-deal roadshow in Hong Kong marks a new milestone in the economic cooperation between the two countries and injects fresh momentum into the high-quality development of the Belt and Road Initiative. Copyright 2024 ACN Newswire via SeaPRwire.com.

London, UK, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - The 3rd edition of the London Climate Technology Show concluded last week, paving a vital roadmap towards fully decarbonising our planet through sustainable technologies. The event brought together policymakers, eco-technology leaders, industry professionals, and innovators, all unified in their call for an immediate shift to sustainable and green solutions to secure a better future for the planet.The two-day event opened on 27th November with an inspiring keynote by Felicity Burch, Executive Director of the Responsible Technology Adoption Unit at the Department for Science, Innovation, and Technology (DSIT), who spoke about AI Innovation in Clean Energy and the DSIT's Manchester Prize. Following her, Ing. Abigail Cutajar, CEO of the Climate Action Authority, talked about Pioneering the Surge Towards Climate and Energy Transitions.The conference unfolded over two dynamic days, featuring a packed agenda of insightful presentations and engaging panel discussions. It delved into actionable strategies for decarbonisation, advancements in AgriTech, the evolving carbon market, eco-funds, energy, CCS, built environment and other groundbreaking innovations in climate technology.Notable discussions highlighted the need for farmers to balance carbon stewardship with food production over the next few decades, the importance of consistent government policies to enable businesses to plan and innovate effectively, and the urgency of addressing digital and engineering skill shortages to ensure a successful green energy transition. Industry experts also called for common sustainability metrics to measure corporate efforts fairly, emphasized the value of collaboration over competition to accelerate the green transition, and underscored the need for farmers to access landscape-level data to enhance biodiversity.The exhibition hall featured groundbreaking innovations and solutions in sustainability and climate technology, including carbon capture and storage (CCS) from companies like CGI and Terra CO2 Technology, carbon management and accounting solutions by Greenly and Gaia Carbon Accounting, and emerging climate technologies from innovators such as Nabla Flow and Luna 9. Other exhibitors showcased AI-driven solutions, sustainable energy systems, and innovative carbon reduction technologies, presenting a comprehensive snapshot of the future of climate tech.#CTS24 also hosted interactive side events, including startup acceleration programs and hands-on workshops, providing participants with opportunities for learning, networking, and collaboration. These sessions empowered attendees to adopt transformative technologies and take decisive climate action.Attendee ExperiencesThe event received overwhelming positive feedback:Mark Haley, Co-founder of Cero3, shared, "We’re so proud to have unveiled our sustainable travel planner. The feedback and interest exceeded our expectations."Satyajit Mohanan, Projects and Business Development Coordinator at Cambridge Cleantech, remarked, "It was a pleasure to be part of this event. I met amazing people and look forward to the next edition."Dennis Chacko, Senior Sales Manager at the British Board of Agreement, shared his excitement over a unique sustainable pen: "Once used, you can plant it to grow something new—a powerful reminder of how everyday items can contribute to a greener future."As this successful edition concludes, the organisers are already planning for a bigger, more impactful 4th Edition, with expanded content and greater opportunities to drive meaningful change toward a sustainable future.For further information, please reach out to us at press@valiantandcompany.com. Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.  VELSIPITY(R) is an effective and convenient, once-daily, oral treatment for patients with moderately-to-severely active UC that has already been approved in the U.S. and E.U., and other countries, by Everest’s licensing partner, Pfizer. In Everest territories, the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China has approved the NDA for VELSIPITY(R) in April of this year and was implemented in the Guangdong-Hong Kong-Macau Greater Bay Area this October through the "Hong Kong and Macau Medicine and Equipment Connect" policy."Autoimmune disease is a core focus and a significant growth driver for our company. The number of UC patients in China is projected to double from 2019 to 2030 to approximately one million, highlighting the urgent need for novel treatments." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Previously, VELSIPITY(R) has already been approved in Macau, China, and was implemented in the Greater Bay Area through the connect policy. The company also plans to submit the NDA for approval by China’s National Medical Products Administration (NMPA) this year, with the aim of benefiting more Chinese patients as soon as possible."" This is an important advancement for etrasimod, bringing hope to patients in Hong Kong, China. This new-generation S1P receptor modulator is an oral, once-daily treatment that can provide patients with a chance for corticosteroid-free remission, mucosal healing, and rapid symptom relief, " said Prof. Wu Kaichun with the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial. “We hope China and other Asian countries can obtain approvals as soon as possible to benefit more patients."The acceptance of the NDA was based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) that evaluated the safety and efficacy of etrasimod 2 mg once-daily on clinical remission in UC patients with moderately to severely active UC who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12 were naïve to biologic or JAK inhibitor therapy, and these studies were also the only studies for advanced therapies for ulcerative colitis to include patients with isolated proctitis. Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod.Everest conducted a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod in Asian countries, including mainland China, China Taiwan and South Korea. This is the largest Phase 3 trial of moderately-to-severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. The previously announced results of the induction period indicate that the clinical remission rate for patients treated with etrasimod 2mg was 25.0%, compared to 5.4% for those treated with placebo (difference 20.4%, p<0.0001). Compared to the placebo group, patients treated with etrasimod demonstrated significant clinical and statistically significant improvements in all key secondary endpoints. Subsequently, the topline results from maintenance period released in July of this year confirmed that after 40 weeks of treatment, etrasimod demonstrated significant clinical and statistical improvements over placebo in the primary and all key secondary endpoints (p<0.0001), and other secondary endpoints (including mucosal healing and endoscopic normalization, both p<0.0001). The safety profile of etrasimod was consistent with previous studies, with no new safety signals observed. The results of the maintenance period will be released at an international academic conference.About VELSIPITY(R) (etrasimod)VELSIPITY(R) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK, Switzerland, Israel and Macau, China for VELSIPITY(R) in ulcerative colitis.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the "Authorization Term"). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, subject to specific conditions stipulated in the Agreement.ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal re-absorption of uric acid by inhibiting Urate Anion Transporter 1 (URAT1). The results of two completed phase 2 clinical trials demonstrated favorable efficacy and safety profiles across multiple dose groups (ranging from 1 mg to 12 mg) of ABP-671. The 2 mg once-daily dosage of the Product was proved to be as effective as, or even better than, benzbromarone or febuxostat (maximum dosage of 80mg). The reduction in uric acid levels was sustained throughout the 24-hour period, with no significant safety concerns identified. This product is anticipated to offer more effective and safer treatment alternatives for patients suffering from gout and hyperuricemia[1]. Multiple patents in regard to substance and use of the ABP-671 have been granted in China.Hyperuricemia is defined as a fasting blood uric acid level exceeding 420μmol/L (7.0 mg/dL) in adults on a normal purine diet on two separate days. The deposition of urate crystals in hyperuricemia patient results in arthritis, medically termed gout. Hyperuricemia and gout can cause acute and chronic inflammatory injury in articular cartilage, bone, kidney and vascular wall, which can lead to multiple organ damage of the heart, brain and kidney, etc. The data presented in the White Paper on Hyperuric Acid and Gout Trends in China (2021) indicates that, the incidence rate of hyperuricemia is 13.3%, with approximately 177 million hyperuricemia patients and the incidence rate of gout is 1.1% in general, with about 14.66 million gout patients in China. Frost & Sullivan indicates that, the number of people with hyperuricemia and gout in China will continue to increase in the future, reaching 240 million and 52.2 million respectively by 2030. Currently, the commonly used uric acid-lowering drugs in clinical practice in China are those which inhibit uric acid synthesis or promote uric acid excretion. Due to certain limitations in the efficacy and safety of the marketed uric acid-lowering drugs, such as causing renal failure, sudden cardiac death or severe liver toxicity. There is still an urgent need for effective and safe uric acid-lowering drugs among gout and hyperuricemia patients in China.ABP-671 is currently with the potential to be the promising and safe product for the treatment of gout and hyperuricemia. Through this collaboration, it fills the blank in the CMS's product portfolio of the treatment of gout. Gout and hyperuricemia are both rheumatic diseases and chronic metabolic diseases, which are highly consistent with the Group's strategic layout in the cardio-cerebrovascular/ gastroenterology business and the network resources of marketed products. If approved for marketing in the future, the Product will synergize with the Group’s marketed product Metoject (methotrexate injection) in rheumatology and with Elcitonin (elcatonin injection) in endocrinology and orthopedics, in terms of expert network and market resources. Based on the unmet clinical needs and the expected solid clinical data of the Product, the Group is looking forward to the smooth advancement of the clinical development of ABP-671, allowing patients with relevant indications to benefit from this innovative treatment sooner.About ATOM THERAPEUTICSAtom Therapeutics was founded in March 2012, focused on the research and development of innovative drugs with global commercial value and competitiveness in the metabolic and inflammatory area. Atom Therapeutics's main core team members come from the United States, with extensive experience in the research and development of innovative drugs. Atom Therapeutics has achieved remarkable development in the past few years. Atom Therapeutics's core product ABP-671 is under pivotal clinical stage for the treatment of chronic gout. Atom Therapeutics's another small molecule innovative drug named as ABP-745, used for indications in the field of anti-inflammatory immune indications. The Phase 1 clinical of ABP-745 exhibited outstanding pharmacokinetics and safety. The clinical trial is on the verge of entering Phase 2. For more information about Atom Therapeutics and its pipeline, please visit https://www.atombp.com/.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. The results of Phase 2 clinical trials was published and can be found at: https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.